GlassScriptPhysician profile
Dennis Albert Jerdan
NPI 1588652200
$7,788.78
in general payments reported to CMS, 2019-2025
29 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $664 · 2021: $665 · 2022: $509 · 2023: $786 · 2024: $2,289 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,123 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,123.39 |
| Education | $118.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,612.33 | 2019-2025 | Evenity, Krystexxa, Tavneos |
| Janssen Biotech, INC. | $1,270.86 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $994.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $669.29 | 2019-2025 | |
| Ucb, INC. | $616.46 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $548.68 | 2023-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $307.38 | 2020-2025 | Orencia |
| Pfizer INC. | $223.60 | 2020-2025 | |
| Ani Pharmaceuticals, INC. | $190.90 | 2024-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $154.48 | 2019-2025 | Tymlos |
| Organon LLC | $146.85 | 2024-2025 | Hadlima, Renflexis |
| Genzyme Corporation | $145.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $127.59 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $115.99 | 2019-2025 | Taltz |
| Genentech USA, INC. | $107.76 | 2019-2025 | Actemra, Rituxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $81.28 | 2024-2025 | |
| Pacira Therapeutics, INC. | $75.43 | 2019 | |
| Horizon Therapeutics Plc | $70.92 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $63.57 | 2019-2024 | Ultomiris |
| Sandoz INC. | $50.44 | 2023-2024 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $49.71 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $29.15 | 2025 | Acthar |
| Tersera Therapeutics LLC | $27.84 | 2024 | Quzyttir |
| Kyowa Kirin, INC. | $25.42 | 2024 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $23.15 | 2025 | Truxima |
| Aurinia Pharma U.S., INC. | $17.15 | 2025 | Lupkynis |
| Tonix Medicines, INC. | $16.20 | 2025 | Tonmya |
| Kiniksa Pharmaceuticals, LTD. | $13.85 | 2023 | Arcalyst |
| Mallinckrodt Enterprises LLC | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Jerdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.